Inclusion Criteria

- INCLUSION CRITERIA:

- Measurable metastatic melanoma or metastatic renal cancer. Metastatic cancer
diagnosis will be confirmed by the Laboratory of Pathology at the National Cancer
Institute (NCI).

- Patients must never have received high dose aldesleukin.

- Greater than or equal to 18 years of age.

- Willing to sign a durable power of attorney

- Able to understand and sign the Informed Consent Document

- Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.

- Life expectancy of greater than three months.

- Patients of both genders must be willing to practice birth control for four months
after receiving treatment.

- Serology:

- Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental
treatment being evaluated in this protocol depends on an intact immune system.
Patients who are HIV seropositive can have decreased immune-competence and thus
be less responsive to the experimental treatment and more susceptible to its
toxicities.)

- Seronegative for hepatitis B antigen and hepatitis C antibody unless antigen
negative.

- Women of child-bearing potential must have a negative pregnancy test because of
the potentially dangerous effects of the therapy on the fetus.

- Hematology:

- Absolute neutrophil count greater than 1000/mm^3 without the support of
filgrastim.

- White blood cell (WBC) (greater than 3000/mm^3).

- Platelet count greater than 100,000/mm^3.

- Hemoglobin greater than 8.0 g/dl.

- Chemistry:

- Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less or
equal to 2.5 times the upper limit of normal.

- Serum creatinine less than or equal to 1.6 mg/dl.

- Total bilirubin less than or equal to 1.5 mg/dl, except in patients with
Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.

- More than four weeks must have elapsed since any prior systemic therapy at the time
the patient receives zanolimumab, and patient's toxicities must have recovered to a
grade 1 or less (except for toxicities such as alopecia or vitiligo).

- Six weeks must have elapsed since prior anti-cytotoxic T-lymphocyte antigen 4 (CTLA4)
antibody therapy to allow antibody levels to decline, and patients who have
previously received anti-CTLA4 antibody and have documented gastrointestinal (GI)
toxicity must have a normal colonoscopy with normal colonic biopsies.

EXCLUSION CRITERIA:

- Women of child-bearing potential who are pregnant or breastfeeding because of the
potentially dangerous effects of the therapy on the fetus or infant.

- Active systemic infections, coagulation disorders or other major medical illnesses of
the cardiovascular, respiratory or immune system, myocardial infarction, cardiac
arrhythmias, obstructive or restrictive pulmonary disease.

- Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
Disease).

- Concurrent opportunistic infections (The experimental treatment being evaluated in
this protocol depends on an intact immune system. Patients who have decreased immune
competence may be less responsive to the experimental treatment and more susceptible
to its toxicities).

- Concurrent systemic steroid therapy

- History of severe immediate hypersensitivity reaction to any of the agents used in
this study. History of coronary revascularization or ischemic symptoms

- Any patient known to have an left ventricular ejection fraction (LVEF) less than or
equal to 45%.

- Documented LVEF of less than or equal to 45% tested in patients with:

- History of ischemic heart disease, chest pain, or clinically significant atrial
and/or ventricular arrhythmias including but not limited to: atrial
fibrillation, ventricular tachycardia, second or third degree heart block

- Age greater than or equal to 60 years old.

- Documented forced expiratory volume 1 (FEV1) less than or equal to 60% predicted
tested in patients with:

- A prolonged history of cigarette smoking (20 pack year of smoking within the
past 2 years).

- Symptoms of respiratory dysfunction